Introduction; M. Schwaiger. Methodology:- 1. Trends in instrumentation; J.T. Spinks, J. Jones. 2. Attenuation correction: Practical considerations; S.L. Bacharach. 3. Radiopharmaceuticals; M.R. Kilbourn. 4. Utility and limitations of (18F)2-deoxy-2-fluoro-D-glucose for the assessment of flux through metabolic pathways in heart muscle: A critical appraisal; H. Taegtmeyer. 5. Quantitative evaluation of myocardial perfusion; G.D. Hutchins, M. Schwaiger. Myocardial Perfusion Imaging:- 6. Assessment of myocardial perfusion with 13N-Ammonia or 82-Rubidium; M. Schwaiger, et al. 7. Assessment of myocardial perfusion with 15-O Water; P. Herrero, S.R. Bergmann. 8. 62Cu-PTSM: A generator-based radiopharmaceutical for myocardial perfusion imaging; M.A. Green. 9. Comparison of cost-effectiveness of myocardial perfusion imaging versus other approaches: Predictions by a model; R.E. Patterson, et al. Assessment of Tissue Viability:- 10. Assessment of blood flow and substrate metabolism in the myocardium of the normal human heart; H.R. Schelbert. 11. Comparison of SPECT and PET for assessment of tissue viability; R. Bonow. 12. 11C-Acetate in ischemic heart disease; R.J. Gropler. 13. Assessment of myocardial viability using 15O-Water; H. Iida, et al. 14. Myocardial 82Rubidium kinetics identify cell membrane integrity and tissue viability; J. vom Dahl, M. Schwaiger. 15. Imaging hypoxic myocardium; G.V. Martin, et al. Other Applications:- 16. Quantification of myocardial oxygen consumption using 11C-Acetate; R. Beanlands, et al. 17. Applications in non-ischemic heart disease and heart failure; R. Beanlands, H.G. Wolpers. 18. The use of PET radiopharmaceuticals to probe cardiac receptors; H. Valette, et al. Appendix:- 19. Clinical PET protocols; J.M. Rothley, A.R.J. Weeden. Index.